Online inquiry

IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6878MR)

This product GTTS-WQ6878MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CX3CL1 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_002996.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6376
UniProt ID P78423
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6878MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ173MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ6658MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DI-17E6
GTTS-WQ1177MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABP 501
GTTS-WQ15412MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TSR-022
GTTS-WQ5920MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CK-301
GTTS-WQ8379MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ13861MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-1979
GTTS-WQ7424MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GA201
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW